Jerry Durso, Intercept Pharmaceuticals CEO

In­ter­cept sells ex-US rights to PBC drug as it gears up for a sec­ond-chance shot at NASH

In­ter­cept Phar­ma­ceu­ti­cals, the biotech that brought NASH to the fore­front of drug de­vel­op­ment R&D, has sold off the ex-US rights to its au­toim­mune dis­ease drug Ocali­va as the com­pa­ny pre­pares the same med for an­oth­er shot at the dis­ease. And with the biotech on tap for a pre-sub­mis­sion meet­ing with the FDA this year in NASH, ex­ecs now have ad­di­tion­al funds to bankroll that work.

Eu­ro­pean spe­cial­ty phar­ma brand Ad­vanz is dish­ing out $405 mil­lion up­front and up to $45 mil­lion more to gain the ex-US rights to Ocali­va, most of In­ter­cept’s in­ter­na­tion­al op­er­a­tions and cer­tain sub­sidiaries, the com­pa­ny said Thurs­day. Tak­en to­geth­er, that’s about the same fig­ure as In­ter­cept’s cash on hand at the end of 2021: $429.4 mil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.